DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE

Stock Information for DermTech Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DermTech Inc

DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
DermTech Reports Fourth-Quarter 2023 Financial Results
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.